Journals / Turkish Neurosurgery / 2014 / Cilt: 24 - Sayı: 3

Travmatik Beyin Hasarının Prognozuyla Ventriküler Beyin Omurilik Sıvısında Matriks Metalloproteinaz-9 Korelasyonu

Matrix metalloproteinase-9 in the Ventricular Cerebrospinal Fluid Correlated with the Prognosis o traumatic Brain ınjury

Pages
363–368
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: MMP-9 concentration in the CSF of TBI patients correlated with neurological outcome and may represent an early indicator for the prognosis of this condition.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Matrix metalloproteinase 9 (MMP-9) has been shown to be a potential biomarker for outcome prediction after neuron damage.
📊
Key Findings & Data:This study investigated whether MMP-9 could be used for outcome prediction after traumatic brain injury (TBI).
💡
Conclusion & Impact:CONCLUSION: MMP-9 concentration in the CSF of TBI patients correlated with neurological outcome and may represent an early indicator for the prognosis of this condition.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AIM: Matrix metalloproteinase 9 (MMP-9) has been shown to be a potential biomarker for outcome prediction after neuron damage. This study investigated whether MMP-9 could be used for outcome prediction after traumatic brain injury (TBI). MATERIAL and METHODS: For the TBI group, cerebrospinal fluid (CSF) was collected at different days after surgery from 6 head injury patients who had received surgical intervention with external ventricular drainage insertion. CSF collected from non-TBI patients (N=85) diagnosed with isolated hydrocephalus by a ventricular puncture during a ventriculo-peritoneal shunt surgery was used as control. RESULTS: The mean concentration of MMP-9 in the CSF of 85 non-TBI patients was determined to be 1.172±0.859 ng/mL. We found that the CSF MMP-9 concentration from TBI patients was elevated immediately after head injury with a median of 1.926 ng/mL (range, 0.673 to 24.990). Despite an early increase in the concentration of MMP-9, levels decreased within 72 hrs and nearly reached the normal range. Nevertheless, the concentration of MMP-9 was negatively correlated with the Glasgow Coma Scale (γ = - 0.337, p = 0.013). CONCLUSION: MMP-9 concentration in the CSF of TBI patients correlated with neurological outcome and may represent an early indicator for the prognosis of this condition.

Özet

AMAÇ: Matriks metalloproteinaz 9un (MMP-9) nöron hasarından sonra sonuçların tahmin edilmesinde olası bir biyobelirteç olduğu gösterilmiştir. Bu çalışma, MMP-9un travmatik beyin hasarından sonra sonucu öngörmek için kullanılıp, kullanılamayacağını incelemiştir. YÖNTEM ve GEREÇLER: Travmatik beyin hasarı grubunda eksternal ventriküler drenaj yerleştirilmesiyle cerrahi girişim yapılmış 6 kafa travması hastasında cerrahi sonrasında farklı günlerde beyin omurilik sıvısı (BOS) toplanmıştır. Kontrol olarak bir ventriküloperitoneal şant cerrahisi sırasında ventriküler ponksiyon ile izole hidrosefali tanısı konmuş, travmatik beyin hasarı olmayan hastalardan BOS toplanmıştır (N=85). BULGULAR: Travmatik beyin hasarı olmayan 85 hastanın BOSunda ortalama MMP-9 konsantrasyonunun 1,172±0,859 ng/mL olduğu bulunmuştur. Travmatik beyin hasarı hastalarında BOS MMP-9 konsantrasyonunun kafa travmasından hemen sonra medyan 1,926 ng/mL (aralık, 0,673 - 24,990) değeriyle yükseldiğini bulduk. MMP-9 konsantrasyonunda erken bir artışa rağmen seviyeler 72 saat içinde azaldı ve hemen hemen normal aralığa döndü. Yine de MMP-9 konsantrasyonu Glasgow Koma Skalası ile negatif korelasyon gösterdi (γ = - 0,337, p = 0,013). SONUÇ: MMP-9 konsantrasyonu travmatik beyin hasarlı hastaların BOSunda nörolojik sonuçla korelasyon gösterdi ve böylece prognoz için erken bir gösterge olabileceği düşünüldü.

🔖

Cite This Article

LIU, C., CHEN, C., LEE, H., CHO, D. (2014). Travmatik Beyin Hasarının Prognozuyla Ventriküler Beyin Omurilik Sıvısında Matriks Metalloproteinaz-9 Korelasyonu. Turkish Neurosurgery, Cilt: 24 - Sayı: 3, 363–368. https://ajindex.com/articles/417843

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Armstead WM, Kiessling JW, Riley J, Cines DB, Higazi AA: tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK. Neurol Res 33:726-733, 2011 2. Barr TL, Latour LL, Lee KY, Schaewe TJ, Luby M, Chang GS, El-Zammar Z, Alam S, Hallenbeck JM, Kidwell CS, Warach S: Blood-brain barrier disruption in humans is independently associated with increased matrix metalloproteinase-9. Stroke 41:e123-e128, 2010 3. Batra A, Latour LL, Ruetzler CA, Hallenbeck JM, Spatz M, Warach S, Henning EC: Increased plasma and tissue MMP levels are associated with BCSFB and BBB disruption evident on post-contrast FLAIR after experimental stroke. J Cereb Blood Flow Metab 30:1188-1199, 2010 4. Candelario-Jalil E, Yang Y, Rosenberg GA: Diverse roles of matrix metalloproteinases and tissue inhibitors of metal- loproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158:983-994, 2009 5. Dash PK, Zhao J, Hergenroeder G, Moore AN: Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7:100-114, 2010 6. De Georgia MA, Deogaonkar A: Multimodal monitoring in the neurocritical intensive care unit. Neurologist 11:45-54, 2005 7. Ghajar J: Essay: The future of traumatic brain injury. Mt Sinai J Med 76:190-193, 2009 8. Gottschall PE, Deb S: Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroim- munomodulation 3:69-75, 1996 9. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA: Eleva- tion of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 65:702-708, 2009 10. Juul N, Morris GF, Marshall SB, Marshall LF: Intracranial hypertension and cerebral perfusion pressure: Influence on neurological deterioration and outcome in severe head injury. The Executive Committee of the International Selfotel Trial. J Neurosurg 92:1-6, 2000 11. Kleindienst A, Meissner S, Eyupoglu IY, Parsch H, Schmidt C, Buchfelder M: Dynamics of S100B release into serum and cerebrospinal fluid following acute brain injury. Acta Neurochir Suppl 106:247-250, 2010 12. Kolar M, Pachl J, Tomasova H, Haninec P: Dymanics of matrix- metalloproteinase 9 after brain trauma--results of a pilot study. Acta Neurochir Suppl 102:373-376, 2008 13. Kövesdi E, Lückl J, Bukovics P, Farkas O, Pál J, Czeiter E, Szellár D, Dóczi T, Komoly S, Büki A: Update on protein biomarkers in traumatic bra